P3 Health Partners Inc. reports developments in population health management, value-based primary care and physician-led care coordination. The company supports community providers through administrative services, clinical operations, data-driven care enablement and partnerships tied to Medicare Advantage, accountable care organizations and delegated-risk arrangements.
Recurring updates include quarterly results, guidance, revenue trends, capitated revenue per member, medical margin, adjusted EBITDA and operating changes in the Care Enablement Model. Company news also covers payer and provider agreements, ACO management services, market expansion, investor conference participation and joint venture activity such as the P3 Commonwealth Innovation MSO.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
P3 Health Partners Inc. (NASDAQ: PIII) reported its Q4 and full-year 2022 financial results, with a notable 40% increase in capitated revenue to $254.0 million. However, the company faced a substantial net loss of $532.3 million, primarily due to a goodwill impairment charge of $463.5 million. For the full year, P3's at-risk Medicare Advantage membership grew by 50% to 100,400, with total revenues reaching $1.0 billion, a 66% increase from the previous year. Looking forward, P3 anticipates achieving Adjusted EBITDA positivity by early 2024 and has provided fiscal 2023 guidance with total revenues projected between $1.2 billion and $1.25 billion.
P3 Health Partners Inc. (NASDAQ: PIII) announced a definitive agreement for a private placement of securities, expected to yield approximately $90 million in gross proceeds. The lead investors are affiliates of Chicago Pacific Founders and Leavitt Partners. The company will issue 79.9 million units at about $1.12 per unit, which includes one share of common stock and 0.75 of a warrant for each unit. The funds will be used for general corporate purposes, and the transaction's closing is anticipated for April 6, 2023.